News FDA knocks back AstraZeneca's self-injected lupus drug FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.
News AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.
News AstraZeneca pays $630m to get full control of AbelZeta CAR-T AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.
News EU starts review of first-line Enhertu for breast cancer EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.
News JPM: Illumina launches 'unprecedented' disease biology atlas Illumina says its new Billion Cell Atlas can be used to identify and validate drug targets and train AI models used in drug discovery.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.